2 weeks Ago By ABMN Staff
Envestnet Asset Management Inc. cut its stake in Bio-Techne Co. ( NASDAQ:TECH – Free Report ) by 11.
2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 349,130 shares of the biotechnology company’s stock after selling 44,093 shares during the quarter. Envestnet Asset Management Inc.
owned about 0.22% of Bio-Techne worth $25,148,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently added to or reduced their stakes in TECH.
Mirae Asset Global Investments Co. Ltd. grew its stake in Bio-Techne by 46.
6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd.
now owns 16,650 shares of the biotechnology company’s stock worth $1,215,000 after buying an additional 5,295 shares during the last quarter. Assenagon Asset Management S.A.
grew its holdings in shares of Bio-Techne by 58.8% during the fourth quarter. Assenagon Asset Management S.
A. now owns 43,298 shares of the biotechnology company’s stock valued at $3,119,000 after buying an additional 16,038 shares during the last quarter. Oddo BHF Asset Management Sas acquired a new position in shares of Bio-Techne in the 3rd quarter valued at $1,188,000.
Fort Washington Investment Advisors Inc. OH raised its stake in Bio-Techne by 11.2% in the 4th quarter.
Fort Washington Investment Advisors Inc. OH now owns 254,034 shares of the biotechnology company’s stock worth $18,298,000 after acquiring an additional 25,650 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in Bio-Techne by 12.
1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 736,340 shares of the biotechnology company’s stock worth $52,641,000 after acquiring an additional 79,629 shares during the last quarter. Hedge funds and other institutional investors own 98.
95% of the company’s stock. Analyst Upgrades and Downgrades Several research analysts have recently issued reports on the company. KeyCorp restated a “sector weight” rating on shares of Bio-Techne in a research note on Wednesday, April 9th.
Royal Bank of Canada raised their price target on shares of Bio-Techne from $79.00 to $80.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 6th.
StockNews.com upgraded shares of Bio-Techne from a “hold” rating to a “buy” rating in a research note on Friday, April 4th. Scotiabank boosted their target price on shares of Bio-Techne from $88.
00 to $90.00 and gave the company a “sector outperform” rating in a research report on Thursday, February 6th. Finally, Evercore ISI started coverage on Bio-Techne in a research report on Tuesday, March 18th.
They set an “outperform” rating and a $75.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock.
According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $81.25. Bio-Techne Price Performance Shares of Bio-Techne stock opened at $50.
72 on Monday. The firm has a market cap of $8.02 billion, a PE ratio of 51.
23, a P/E/G ratio of 2.88 and a beta of 1.45.
Bio-Techne Co. has a twelve month low of $46.44 and a twelve month high of $85.
57. The company has a quick ratio of 2.77, a current ratio of 3.
94 and a debt-to-equity ratio of 0.14. The business has a 50-day moving average price of $61.
32 and a 200 day moving average price of $69.53. Bio-Techne ( NASDAQ:TECH – Get Free Report ) last announced its earnings results on Wednesday, February 5th.
The biotechnology company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.
03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.
22%. Sell-side analysts predict that Bio-Techne Co. will post 1.
67 earnings per share for the current fiscal year. Bio-Techne Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Friday, February 28th. Shareholders of record on Monday, February 17th were issued a dividend of $0.
08 per share. This represents a $0.32 annualized dividend and a yield of 0.
63%. The ex-dividend date of this dividend was Friday, February 14th. Bio-Techne’s payout ratio is 24.
24%. Insider Activity In related news, CEO Kim Kelderman sold 13,392 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $77.
29, for a total transaction of $1,035,067.68. Following the completion of the sale, the chief executive officer now directly owns 39,004 shares in the company, valued at approximately $3,014,619.
16. The trade was a 25.56 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, Director Amy E. Herr sold 1,860 shares of the firm’s stock in a transaction on Friday, February 14th.
The shares were sold at an average price of $65.96, for a total value of $122,685.60.
Following the completion of the transaction, the director now owns 1,976 shares in the company, valued at $130,336.96. The trade was a 48.
49 % decrease in their position. The disclosure for this sale can be found here . Company insiders own 3.
90% of the company’s stock. About Bio-Techne ( Free Report ) Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. See Also Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Bio-Techne Co. ( NASDAQ:TECH – Free Report ). Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.
com's FREE daily email newsletter ..
